Cabaletta Bio Inc (CABA)

Apr 25, 2025

CABA’s Financial Health: Exploring Cabaletta Bio Inc’s Debt-to-Equity Ratio of 1.79 - investchronicle.com

Apr 25, 2025

Apr 24, 2025

Is Cabaletta Bio Inc (CABA) a good investment opportunity? - uspostnews.com

Apr 24, 2025

Apr 24, 2025

American Superconductor Corp (AMSC) requires closer examination - uspostnews.com

Apr 24, 2025

Apr 24, 2025

Aehr Test Systems (AEHR) shows promising results - uspostnews.com

Apr 24, 2025

Apr 15, 2025

Wellington Management Group LLP Has $409,000 Stock Position in Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World

Apr 15, 2025

Apr 09, 2025

Cabaletta Bio Q1 EPS Estimate Increased by HC Wainwright - MarketBeat

Apr 09, 2025

Apr 08, 2025

William Blair Boosts Earnings Estimates for Cabaletta Bio - MarketBeat

Apr 08, 2025

Apr 08, 2025

William Blair Forecasts Cabaletta Bio Q1 Earnings - MarketBeat

Apr 08, 2025

Apr 07, 2025

Cabaletta Bio, Inc. (NASDAQ:CABA) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat

Apr 07, 2025

Apr 06, 2025

Cabaletta Bio to Present Pioneering Clinical Data on Rese-cel at Major Scientific Conferences - MSN

Apr 06, 2025

Apr 06, 2025

Cabaletta Bio (NASDAQ:CABA) Price Target Cut to $3.00 by Analysts at Wells Fargo & Company - MarketBeat

Apr 06, 2025

Apr 05, 2025

HC Wainwright Weighs in on Cabaletta Bio FY2029 Earnings - MarketBeat

Apr 05, 2025

Apr 05, 2025

Cantor Fitzgerald Weighs in on Cabaletta Bio FY2025 Earnings - MarketBeat

Apr 05, 2025

Apr 05, 2025

UBS Group Issues Pessimistic Forecast for Cabaletta Bio (NASDAQ:CABA) Stock Price - MarketBeat

Apr 05, 2025

Apr 05, 2025

Thrivent Financial for Lutherans Buys New Stake in Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World

Apr 05, 2025

Apr 05, 2025

Cabaletta Bio (NASDAQ:CABA) Posts Quarterly Earnings Results, Hits Expectations - MarketBeat

Apr 05, 2025

Apr 05, 2025

Q1 EPS Estimates for Cabaletta Bio Raised by HC Wainwright - Defense World

Apr 05, 2025

Apr 05, 2025

Cabaletta Bio (NASDAQ:CABA) Given Buy Rating at Guggenheim - MarketBeat

Apr 05, 2025

Apr 05, 2025

William Blair Increases Earnings Estimates for Cabaletta Bio - Defense World

Apr 05, 2025

Apr 04, 2025

Cabaletta Bio (NASDAQ:CABA) Issues Earnings Results, Meets Estimates - MarketBeat

Apr 04, 2025

Apr 04, 2025

Cabaletta Bio (NASDAQ:CABA) Receives Buy Rating from HC Wainwright - MarketBeat

Apr 04, 2025

Apr 04, 2025

William Blair Comments on Cabaletta Bio Q1 Earnings - Defense World

Apr 04, 2025

Apr 04, 2025

Cabaletta Bio Reports Strong Clinical Progress and Q4 2024 Financial Results - MSN

Apr 04, 2025

Apr 04, 2025

Analysts Offer Predictions for Cabaletta Bio FY2029 Earnings - Defense World

Apr 04, 2025

Apr 04, 2025

FY2025 EPS Forecast for Cabaletta Bio Raised by Analyst - Defense World

Apr 04, 2025

Apr 03, 2025

Cabaletta Bio stock hits 52-week low at $1.15 amid sharp decline By Investing.com - Investing.com South Africa

Apr 03, 2025

Apr 03, 2025

Kaskela Law LLC Announces Stockholder Investigation of Cabaletta Bio, Inc.CABA - ACCESS Newswire

Apr 03, 2025

Apr 03, 2025

Cabaletta Bio stock hits 52-week low at $1.15 amid sharp decline - Investing.com

Apr 03, 2025

Apr 03, 2025

Cabaletta Bio, Inc. (NASDAQ:CABA) Given Average Recommendation of “Buy” by Analysts - Defense World

Apr 03, 2025

Apr 02, 2025

Cabaletta Bio (NASDAQ:CABA) Price Target Cut to $22.00 by Analysts at Morgan Stanley - MarketBeat

Apr 02, 2025

Apr 02, 2025

Charles Schwab Investment Management Inc. Sells 16,585 Shares of Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World

Apr 02, 2025

Apr 02, 2025

Cabaletta Bio’s (CABA) “Buy” Rating Reaffirmed at Guggenheim - Defense World

Apr 02, 2025

Apr 02, 2025

Cabaletta Bio (NASDAQ:CABA) Given New $3.00 Price Target at Wells Fargo & Company - Defense World

Apr 02, 2025

Apr 02, 2025

Wells Fargo & Company Cuts Cabaletta Bio (NASDAQ:CABA) Price Target to $3.00 - Defense World

Apr 02, 2025

Apr 02, 2025

Cabaletta Bio Advances T Cell Therapies for Autoimmune Diseases - TipRanks

Apr 02, 2025

Apr 01, 2025

UBS cuts Cabaletta Bio stock target to $7, maintains Buy rating - Investing.com Australia

Apr 01, 2025

Apr 01, 2025

Cabaletta Bio’s Strategic Advances in Myositis Treatment Drive Buy Rating - TipRanks

Apr 01, 2025

Apr 01, 2025

UBS cuts Cabaletta Bio stock target to $7, maintains Buy rating By Investing.com - Investing.com South Africa

Apr 01, 2025

Apr 01, 2025

Is Cabaletta Bio Inc (CABA) worth investing in despite its undervalued state? - uspostnews.com

Apr 01, 2025

Apr 01, 2025

UBS Adjusts Price Target on Cabaletta Bio to $7 From $10, Keeps Buy Rating - MarketScreener

Apr 01, 2025

Apr 01, 2025

Cabaletta Bio price target lowered to $22 from $30 at Morgan Stanley - TipRanks

Apr 01, 2025

Apr 01, 2025

Cabaletta Bio: Strong Clinical Progress and Financial Stability Drive Buy Rating - TipRanks

Apr 01, 2025

Apr 01, 2025

Stifel cuts Cabaletta Bio stock target to $13, maintains buy By Investing.com - Investing.com Canada

Apr 01, 2025

Mar 31, 2025

Stifel cuts Cabaletta Bio stock target to $13, maintains buy - Investing.com

Mar 31, 2025

Mar 31, 2025

Cabaletta Bio Reports Wider Q4 Results As R&D Expenses Rise - Nasdaq

Mar 31, 2025

Mar 31, 2025

BIT Capital GmbH Invests $431,000 in Cabaletta Bio, Inc. (NASDAQ:CABA) - MarketBeat

Mar 31, 2025

Mar 31, 2025

Cabaletta Bio Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 31, 2025

Mar 31, 2025

Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - The Manila Times

Mar 31, 2025

Mar 31, 2025

Cabaletta Bio, Inc. SEC 10-K Report - TradingView

Mar 31, 2025